Kevin Duffy Profiting from this Impending Stock Market Decline

Kevin Duffy of Bearing Asset Management thinks we are facing another major bear market.

Kevin Duffy thinks that this 8 year bull market has been one of the most anemic recoveries since World War II. Also, valuations are very stretched. Duffy thinks we are in a stimulus bubble.

The Tech Bubble was very narrow. The Credit Bubble was a bit more broader as it was focused on housing. This Stimulus Bubble we are in now is a very broad based bubble.

There is a tremendous amount of leverage in the system with margin debt hitting all-time highs.

Kevin Duffy lays out a powerful case for why we need to be defensive and on the alert for a stock market crash.

Kevin Duffy Profiting from this Impending Stock Market Decline

Sell TRC Companies For a Monster 72% Win!

March 31, 2017: Sell TRC Companies for a monster +72% win and congratulations if you were able to make money on the trade. TRC Companies announced that it has entered into a definitive merger agreement with affiliates of New Mountain Partners IV, L.P., an investment fund managed by New Mountain Capital, LLC, a leading growth-oriented investment firm headquartered in New York, under which New Mountain will acquire TRC in an all cash transaction valued at $17.55 per share of common stock.

January 17, 2017: TRC Companies acquired the contract to serve as Program Administrator of New Jersey’s Clean Energy Program (NJCEP), which has provided more than $300 million annually in support to homeowners, businesses and government entities upgrading to high-efficiency and renewable energy technology.

All the staff who have been working for the prior NJCEP Administrator, Ameresco Inc. and its wholly owned subsidiary, Applied Energy Group Inc. (AEG), will be joining TRC. Financial terms of the transaction were not disclosed.

TRC and AEG anticipate the transition will be seamless, with the same team continuing in its existing role without interruption. TRC’s Energy Efficiency practice is a growing, national leader in the design and implementation of state energy efficiency programs and provides services similar to the administration of NJCEP in several other states.

November 28, 2016: Sidoti initiates coverage of TRC Companies with a Buy rating and a price target of $14.

TRC is a national engineering, consulting and construction management firm providing integrated services to the power, environmental, infrastructure and oil and gas markets. We serve a broad range of clients in government and industry, implementing complex projects from initial concept to operations.

Stock Market Rallies After Globalist Attempt To Crash It, Trump Fights On

God Bless Alex Jones. I appreciate Alex Jones defending President Trump but I think the globalists and corporate elites have the power to crash the stock market anytime they want.

I have to disagree with Alex Jones that the $3 trillion in value in the stock market since President Trump was elected is good. I believe it’s a bad thing as its price manipulation (not fundamentals) in order to suck in more amateur investors so that they can sell their stock to and get out. Remember, for a sale to occur at a specific price, someone has to be willing to buy. Institutions trade against amateur traders like you and me. Institutions buy first like they did in March of 2009, and they sell first like some are starting to do right now. Institutional buying cause ‘V’ bottoms. Institutional selling causes sideways volatile tops. The reason that institutional selling causes sideways market action at tops is that they hold too many shares and even by using dark pools, they still can’t dump their positions all at once. They slowly and secretly unwind their positions while sucking in more and more amateur traders with price manipulation. Once they are done unwinding their positions, they short the market and take billions of dollars from amateur traders and investors. Amateurs panic and sell and get out of the stock market which pushes up the profits for institutional traders. Once the market is down to a good valuation and deep discount as the mainstream media is running stories about how the sky is falling, institutional traders are the first to get back on the long side and the entire cycle repeats again.

This cycle means that institutional traders always win as they feed off of amateur traders because they have the buying power to move the entire market unlike amateur traders. Institutional traders collude with the Federal Reserve and rate hikes, to set the Bull/Bear cycle because of their immense buying power. This is why I have to disagree with Alex Jones about the stock market and how globalists are trying to crash it. They don’t have to “try”, they can and will crash it at anytime they desire. Nevertheless, I don’t have to agree with Alex Jones 100% of the time to love his show and ideas. Here is the Alex Jones show and you can decide for yourself if you agree with his assessment or not.

Stock Market Rallies After Globalist Attempt To Crash It ⁄ Trump Fights On

New Ground Defense Technology

Using existing technology defense contractors have available today, a wicked new ground defense technology could destroy an entire Tank Company in minutes. The publisher of the video below says that this technology is being worked on. I would like to know the US defense contractor that is working on this as I think it would be bigger than the Patriot Defense Missile System. I have little doubt that the Chinese would love to get their hands on this technology.

New Ground Defence by using modern technology

Market Alert! Brexit Coming as Trump Tax Cuts Delayed

This week’s show features commentary on the massive wave of retail stores closing, Brexit and Article 50 to be invoked on March 29, the chilling plunge in bank loan creation, President Trump’s flip on extending the debt ceiling, the fantasy Trump rally ending, the fake news Trump has ties with Russia and the Devin Nunes revelation, Judge Napolitano’s canceled show on Fox News channel, Saudi Arabia’s huge production cut, the surge in attacks against US Border Patrol agents by Mexico and Mexico’s attack on the California pension system courtesy of traitor Democrats like Lorena Fletcher and Bill 946, and more.

Jazz Pharmaceuticals Announces Positive Results From Phase 3 TONES 3 and TONES 4

March 20, 2017: Jazz Pharmaceuticals announced positive efficacy results from two global multicenter studies in adult patients with excessive sleepiness associated with obstructive sleep apnea (OSA). JZP-110 demonstrated highly statistically significant differences in the co-primary efficacy endpoints in the TONES 3 study at the 300 mg, 150 mg, 75 mg and 37.5 mg dose arms and in the TONES 4 study in the combined JZP-110 treatment arm (300 mg, 150 mg, and 75 mg doses) compared to placebo. Based on the preliminary safety analysis, the most commonly reported adverse events (AEs) in these studies were consistent with those previously described in the Phase 2 clinical studies evaluating JZP-110 in narcolepsy.

The Treatment of OSA and Narcolepsy Excessive Sleepiness (TONES) Phase 3 program is comprised of four studies, two in OSA, one in narcolepsy and one open-label, long-term safety and maintenance of efficacy study. The two Phase 3 OSA studies enrolled 652 total patients.
Efficacy Results of TONES 3 Study The TONES 3 study, or 14-003, is a 5-arm, parallel-group study evaluating four doses of JZP-110 (300 mg, 150 mg, 75 mg and 37.5 mg) and placebo for a 12-week period. The study enrolled 476 patients and was powered to detect differences between placebo and the 300 mg and 150 mg dose arms.

In TONES 3, JZP-110 demonstrated highly statistically significant improvement in the co-primary endpoints of Maintenance of Wakefulness test (MWT) and Epworth Sleepiness scale (ESS) at all doses. In addition, the key secondary endpoint of Patient Global Impression of Change (PGIc) scale demonstrated a highly statistically significant improvement in the 300 mg, 150 mg and 75 mg doses versus placebo. On the co-primary endpoints of MWT and ESS, the study demonstrated that treatment with JZP-110 significantly increased the patients’ ability to stay awake and significantly decreased patients’ subjective levels of sleepiness, respectively, compared to placebo. These effects were maintained throughout the course of the study.
Efficacy Results of TONES 4 Study The TONES 4 study, or 14-004, is a six-week study in which eligible subjects received four weeks of open-label treatment, and at the end of week 4, 126 patients who reported “much” or “very much” improvement on the PGIc scale and who had numerical improvements on the MWT and ESS at week 4 were then randomized 1:1 to receive either the same dose of JZP-110 received in the stable dose phase, or placebo, for two weeks in the randomized withdrawal phase.

In TONES 4, patients randomized to continue on JZP-110 maintained efficacy, while those randomized to placebo experienced a loss of efficacy, as measured by the co-primary and key secondary endpoints.

Preliminary Safety Results of TONES 3 and TONES 4 Studies Based on a preliminary safety analysis, the most commonly reported adverse events were headache, nausea, decreased appetite, dry mouth, anxiety, dizziness, insomnia, nasopharyngitis, and palpitations. There were six patients with serious adverse events (SAEs), two patients on placebo and four on JZP-110. None of these was deemed a treatment-related adverse event as assessed by the investigators. Additional safety information will be available based on the final analyses of the JZP-110 program, including results of the open-label, long-term safety and maintenance of efficacy study.

January 18, 2017: Leerink reiterates their Outperform rating on Jazz Pharmaceuticals and sets a price target of $182 after yesterday evenings FDA updates regarding a generic Xyrem (naracolepsy) application appear to be a net-positive for JAZZ as the FDA concurrently ruled (in a citizens petition [CP]) that it won’t allow generic substitutes to carve-out safety/dosing language that is patent protected. At a minimum, firm expects the approved generic will need to successfully litigate the Xyrem formulation (ends mid-2020E) and DDI patents (expires 2033E) before launching as they believe an at-risk launch against two battletested patent families would be financial catastrophic. Ultimately, todays update provides much needed visibility into how the FDA views the safety risk of omitting divalproex DDI (drug-drug interaction) and dosing language from the Xyrem package insert. Some investors believed generic companies’ ability to “carve out” the DDI information from their labels would allow them to argue they didn’t infringe the DDI patents. Based on last night’s ruling, it would appear this generic noninfringement strategy on the DDI patents is foreclosed. Further, with JAZZs DDI patents withstanding the invalidity challenge in multiple inter partes reviews (IPR) relating to the obviousness of those patents, those patents now appear much stronger and likely to withstand two central arguments they’d anticipate when the patent dispute moves to the district court in May 2017 (lead case). Based on the above considerations, firm believes the generic companies will be more likely to accept JAZZ’s likely settlement offer to launch in late 2025E since the risk of getting blocked until 2033E looks increasingly probable.

January 17, 2017: The U.S. Food and Drug Administration (FDA) has approved Jazz’s Xyrem, the first generic version of Xyrem (sodium oxybate) Oral Solution, to treat cataplexy and excessive daytime sleepiness in patients with narcolepsy, which is a potentially debilitating disease. Cataplexy is a primary symptom of narcolepsy where patients suddenly lose muscle tone, including voluntary muscle control, while awake. Muscle weakness or paralysis associated with cataplexy may cause a person to collapse. Approximately 70 percent of people with narcolepsy have cataplexy. Sodium oxybate is the only medication approved to treat cataplexy in patients with narcolepsy.

The use of Xyrem has been associated with serious side effects including seizures, trouble breathing, changes in alertness, coma, and death. Additionally, the active ingredient in Xyrem (and in the newly approved generic) is sodium oxybate. Sodium oxybate is the sodium salt of gamma-hydroxybutyrate (GHB). GHB has not been approved for any medical use and has the potential for abuse, such as in cases of sexual assault.

Because of the potential risks associated with Xyrem, it is subject to strict safety controls on prescribing and dispensing under a program called a Risk Evaluation and Mitigation Strategy (REMS). FDAs approval of generic sodium oxybate is subject to a REMS with strict safety controls that are comparable to those currently required for Xyrem.

Specifically, under both the Xyrem REMS and the generic sodium oxybate REMS, sodium oxybate can be prescribed only by a certified prescriber, and dispensed only to an enrolled patient by a certified pharmacy. Only a certified pharmacy that ships directly to patients can dispense sodium oxybate. Sodium oxybate will not be available in retail pharmacies.

In approving this generic version of Xyrem, the FDA is maintaining strict safety requirements for sodium oxybate, while providing patients with access to a generic medication option for narcolepsy. Source: http://www.fda.gov/Drugs/DrugSafety/ucm537281.htm

January 9, 2017: At the JP Morgan conference, Jazz said it plans to expand via M&A and partnerships this year; Affirms FY16 $9.90-10.30 versus $10.02 estimate; Revenue $1.5 billion versus $1.49 billion estimates.

December 15, 2016: Cantor Fitzgerald initiates JAZZ with an Overweight rating and a price target of $187.

Jazz Pharmaceuticals plc is an international biopharmaceutical company focused on improving patients’ lives by identifying, developing and commercializing important products that address unmet medical needs. The company has a diverse portfolio of products and product candidates with a focus in the areas of sleep and hematology/oncology.

As part of our unwavering commitment to improving patients’ lives, we are continuing to expand our commercial product portfolio and our research and development pipeline in therapeutic areas that can leverage our unique expertise. We do this through a growth strategy of growing sales of the existing medicines in our portfolio; acquiring commercial products or product candidates that are in late-stage development, and pursuing focused development of our pipeline of differentiated therapies.

Saturday Night Show: Janet Yellen Rate Hike While Pension Plans Going Broke

Help us spread the word about the growing conservative America first movement. We’re reaching thousands, help us reach millions by sharing this show with your family and friends.

A weekly Saturday financial show that attempts to predict market direction for the week ahead by looking at a variety of fundamental and technical charts. This week’s show features commentary on Janet Yellen and the Federal Reserve’s strange timing of a rate hike, how Obama Administration diverted FNMA money and investors dividends into Affordable Care Act to keep it solvent, and the collapsing pension funds across America.

Information Wars: Saturday Night Live Textbook Case In Mind Control By Globalists

Saturday Night Live did a hit-piece against President Trump and Alex Jones last night. This is a textbook case in mainstream media mind control. You have to be aware of this as you get your news from globalist controlled media groups like CNBC and Fox Business. Like with the WSJ, you have to ask yourself why do they want me to think this way about the economy or a certain stock or sector. For example, I think that the OPEC oil production cut deal is about ready to fall apart because of certain stories last week in the news even though CNBC won’t have anyone on their network saying that right now. Just like CNBC refused to be critical of Saudi Arabia as they were targeting the shale oil industry in this country several years ago that resulted in Americans losing tens-of-thousands of good pay jobs.

Alex Jones does a brilliant job breaking down what the globalists are attempting to accomplish in this Saturday Night Live attack cleverly cloaked in humor.

This is nothing less than “lone wolf” activation in an attempt to take President Trump out when SNL reinforces the stereotype they created that President Trump is a racist out to get black people. Check out the textbook mind manipulation skit from SNL below.

Governments, Tech Firms Respond to Vault 7

Governments around the world are starting to respond to Vault 7.

Governments are using a classic strawman and showing outrage at who could have leaked this information instead of showing outrage at the fact that the CIA has created this incredible invasion of privacy by infecting consumer products with nasty viruses and malware. Nobody is even denying that the CIA has this technology or may have been using it to spy on political opponents with to blackmail and influence the outcomes of elections.

Germany’s top prosecutor has said they will examine the documents in Vault 7 and prosecute accordingly, if evidence of criminal acts is found. Meanwhile, Samsung has begun a probe into their products’ vulnerabilities and Apple has stated they will “continue work to rapidly address any identified vulnerabilities.” Other tech companies have also responded to the Vault 7 revelations. RT America’s Anya Parampil reports.

Governments, tech firms respond to Vault 7

Impractical Jokers – My Stock Market Advisor

Joe knows a thing or two when it comes to the shhhhtock market.

If laughter is contagious, these guys should be quarantined! Q, Sal, Joe and Murr have entertained each other for years with the most hilarious practical jokes they could imagine. Now these real-life best friends are challenging each other to the most outrageous dares and uproarious stunts ever to be caught on hidden camera.

Impractical Jokers – My Stock Market Advisor